Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 4 October 2023, 17:03 HKT/SGT
Share:
    

Source: Hitachi, Ltd.
Hitachi's Proton Therapy System Now in Use at National Cancer Centre Singapore

TOKYO, Oct 4, 2023 - (JCN Newswire) - Hitachi, Ltd. (TSE:6501, "Hitachi") and Hitachi Asia Ltd. announced today that it has delivered to National Cancer Centre Singapore ("NCCS") a proton therapy system, with which NCCS has completed the first patient treatment as of 11 August 2023. This marks Hitachi's first proton therapy system to start treatment in Southeast Asia.

Treatment Room

This system, installed in the basement of the new building of NCCS with 24 floors above ground, consists of five treatment rooms, four with rotating gantries and one with fixed beam, equipped with Real-time image Gating system for Proton Therapy (RGPT) to treat tumors in motion due to respiration and advanced spot scanning technology to irradiate even tumors with complex shapes with high precision.

NCCS is a leading national and regional tertiary cancer centre with specialists who are experts in treating cancer. The new NCCS building which officially opened on May 18th this year, has increased capacity and expanded facilities dedicated to cancer treatment, rehabilitation, research and education all under one roof.

Hitachi provides products and services of particle therapy systems with higher performance and added value, which can be found in leading hospitals around the world, ranging from proton therapy system, heavy ion therapy system to hybrid system combined with the capabilities of proton and carbon therapy. With over 85,000 patients* treated to date, the systems have an excellent reputation for reliability.

*Statistics based on data up to December 2021 published on the PTCOG's website.

Hitachi will continue to support patient-friendly treatment and improvement of the quality of life (QoL) for cancer patients and contribute to the further development of minimally invasive cancer treatments.

Overview of Particle Therapy

Particle Therapy is an advanced type of cancer radiotherapy. Protons extracted from hydrogen atoms, or carbon ions are accelerated up to 70% of the speed of light. This energy is concentrated directly on the tumor while minimizing radiation dose to surrounding healthy tissue. Particle therapy improves the quality of life for cancer patients since the patient experiences no pain during treatment and the procedure has very few side effects compared to that of traditional radiotherapy. In most cases, patients can continue with their normal daily activities while undergoing treatment.

About Hitachi, Ltd.

Hitachi drives Social Innovation Business, creating a sustainable society through the use of data and technology. We solve customers' and society's challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products. Hitachi operates under the business structure of "Digital Systems & Services" - supporting our customers' digital transformation; "Green Energy & Mobility" - contributing to a decarbonized society through energy and railway systems, and "Connective Industries" - connecting products through digital technology to provide solutions in various industries. Driven by Digital, Green, and Innovation, we aim for growth through co-creation with our customers. The company's consolidated revenues for fiscal year 2022 (ended March 31, 2023) totaled 10,881.1 billion yen, with 696 consolidated subsidiaries and approximately 320,000 employees worldwide. For more information on Hitachi, please visit the company's website at https://www.hitachi.com.

About Hitachi Asia, Ltd.

Hitachi Asia Ltd., (Hitachi Asia) a subsidiary of Hitachi, Ltd., is headquartered in Singapore. With offices across seven ASEAN countries Indonesia, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam – Hitachi Asia and Hitachi's subsidiary companies offer IT, OT (Operational Technology) and products to support customers in their transformation journeys. We will contribute to the growth in the ASEAN region by co-creating with customers to identify the social challenges and needs and deliver the solutions. For more information on Hitachi Asia, please visit the company's website at https://www.hitachi.asia/




Topic: Press release summary
Source: Hitachi, Ltd.

Sectors: MedTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2023 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Hitachi, Ltd. Links

http://www.hitachi.com

https://www.facebook.com/hitachi.global/

https://twitter.com/hitachiglobal?lang=en

https://www.youtube.com/user/HitachiBrandChannel

https://ph.linkedin.com/company/hitachi

Hitachi, Ltd.
Nov 28, 2023 16:43 HKT/SGT
Hitachi awarded Sustainable Markets Initiative 2023 Terra Carta Seal
Nov 22, 2023 19:05 HKT/SGT
Hitachi Energy unveils new emission-free alternative to diesel- powered generators
Nov 10, 2023 14:12 HKT/SGT
Hitachi Energy wins order to upgrade world-record high-voltage direct current transmission system
Nov 7, 2023 19:47 HKT/SGT
Hitachi receives top "Gold" award in "Pride Index 2023"
Nov 2, 2023 17:10 HKT/SGT
Hitachi to transfer Hitachi Power Semiconductor Device shares to MinebeaMitsumi for further growth and corporate value enhancement of Hitachi Power Semiconductor Device
Nov 1, 2023 09:15 HKT/SGT
Hitachi Rail secures clearance for EUR1,660m Thales GTS acquisition
Oct 24, 2023 17:10 HKT/SGT
Hitachi Energy acquires eks Energy
Oct 12, 2023 11:51 HKT/SGT
Hitachi Announces Consolidation of Healthcare Business into Hitachi High-Tech through Company Split
Sept 19, 2023 19:06 HKT/SGT
Hitachi Industrial Products to Launch High-capacity Multi-port EV Charger
Sept 12, 2023 12:32 HKT/SGT
Aflac, Hitachi, and GlobalLogic Collaborate to Create an Ecosystem to Support Employees with Cancer
More news >>
 News Alerts
Copyright © 2023 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: